Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第6页

Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review. 尼达尼布与吡非尼酮治疗特发性肺纤维化的成本-效果：系统评价

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-24 DOI: 10.1080/14737167.2025.2480718

Aziz Rezapour, Mohammad Veysi-Sheikhrobat, Aghdas Souresrafil, Sajad Moeini, Tayebe Roghani, Abdollah Sayyad, Ahmad Tahmasebi-Ghorrabi

{"title":"Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review.","authors":"Aziz Rezapour, Mohammad Veysi-Sheikhrobat, Aghdas Souresrafil, Sajad Moeini, Tayebe Roghani, Abdollah Sayyad, Ahmad Tahmasebi-Ghorrabi","doi":"10.1080/14737167.2025.2480718","DOIUrl":"10.1080/14737167.2025.2480718","url":null,"abstract":"Introduction: Objective: To systematically review studies on the cost-effectiveness of pirfenidone compared to nintedanib in patients with idiopathic pulmonary fibrosis (IPF).Methods: Data sources: PubMed, EMBASE, Scopus, and Web of Science. Inclusion criteria: Full economic evaluations comparing pirfenidone versus nintedanib inIPF patients. Assessment: Quality of Health Economic Studies (QHES) tool forstudy quality.Results: Nine studies met the inclusion criteria with QHES scores of 0.91 or higher. The incremental cost-effectiveness ratios (ICERs) ranged from $66,434 to $1,668,321 per quality-adjusted life year (QALY) in the United States. Nintedanib was found to be cost-effective in five studies.Conclusions: Nintedanib appears to be a more cost-effective treatment for IPF compared to pirfenidone. Further research is needed, particularly in low- and middle-income countries, considering healthcare system perspectives and varied willingness-to-pay thresholds.Registration: PROSPERO (CRD42024543954).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"661-669"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of blood-based colorectal cancer screening - a simulation model incorporating real-world longitudinal adherence. 基于血液的结直肠癌筛查的成本效益-一个结合真实世界纵向依从性的模拟模型。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.1080/14737167.2025.2458044

Elifnur Yay Donderici, Shaun P Forbes, Nicole J Zhang, Gregory Schafer, Victoria M Raymond, Amar K Das, Craig Eagle, AmirAli Talasaz, William M Grady

{"title":"Cost-effectiveness of blood-based colorectal cancer screening - a simulation model incorporating real-world longitudinal adherence.","authors":"Elifnur Yay Donderici, Shaun P Forbes, Nicole J Zhang, Gregory Schafer, Victoria M Raymond, Amar K Das, Craig Eagle, AmirAli Talasaz, William M Grady","doi":"10.1080/14737167.2025.2458044","DOIUrl":"10.1080/14737167.2025.2458044","url":null,"abstract":"Objectives: Although U.S. Preventive Services Task Force (USPSTF) recommended CRC screenings are effective; patient reluctance reduces adherence. Most cost-effectiveness models assume perfect adherence, yet one-third of eligible individuals aren't current with CRC screening. Our study assesses the cost-effectiveness of Shield, an FDA-approved blood-based CRC screening test, using real-world adherence.Methods: The CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model, a validated discrete-event simulation, evaluated clinical and economic outcomes of CRC screening under real-world adherence scenarios. We compared the Shield blood-based test administered every 3 years to no screening, considering it cost-effective if the incremental cost-effectiveness ratio (ICER) was under $100,000 per quality-adjusted life-year (QALY) gained.Results: Shield increased QALYs by 154 and raised costs by $7.5 million per 1,000 individuals, with an ICER of $48,662 per QALY, meeting the $100,000/QALY threshold. Shield remained cost-effective up to a unit cost of $3,241 (at $100,000/QALY) and $4,942 (at $150,000/QALY). Sensitivity analyses confirmed cost-effectiveness with lower adherence to diagnostic colonoscopy (56.1%) and annual screenings.Conclusion: The CAN-SCREEN model shows that Shield is cost-effective compared to no screening. Including real-world adherence improves accuracy in assessing screening strategies. Shield's noninvasive approach offers a promising, cost-effective way to increase adherence and reduce CRC mortality.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"671-677"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore. 曲妥珠单抗emtansine在新加坡用于HER2+晚期乳腺癌二线治疗的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-01-22 DOI: 10.1080/14737167.2025.2456065

Wei Han Melvin Wong, Raymond Ng, Mohamed Ismail Abdul Aziz, Benjamin Shao-Kiat Ong, Kwong Ng

{"title":"Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore.","authors":"Wei Han Melvin Wong, Raymond Ng, Mohamed Ismail Abdul Aziz, Benjamin Shao-Kiat Ong, Kwong Ng","doi":"10.1080/14737167.2025.2456065","DOIUrl":"10.1080/14737167.2025.2456065","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of trastuzumab emtansine (T-DM1) compared to both lapatinib plus capecitabine (lapcap) and trastuzumab plus capecitabine (trascap) for treating human epidermal growth factor 2-positive advanced breast cancer patients, who have received prior treatment with trastuzumab and a taxane, in Singapore.Research design and methods: A three-state partitioned survival model was used to evaluate the cost-effectiveness from the local healthcare system perspective. Key effectiveness data, including progression-free survival and overall survival from the pivotal EMILIA trial, were used alongside local clinician inputs. Health state utilities (in quality-adjusted life years [QALYs]) were obtained from the literature and direct medical costs obtained from the public health institutions in Singapore. Scenario, one-way, and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on cost-effectiveness.Results: The base-case incremental cost-effectiveness ratios (ICERs) for T-DM1, compared to lapcap and trascap, were S$472,600 and S$495,200 per QALY gained, respectively. Sensitivity and scenario analyses showed high ICERs, with a 50% price reduction for T-DM1 resulting in an ICER above S$200,000.Conclusion: At current prices, T-DM1 is unlikely to be a cost-effective use of Singapore's limited healthcare budget. These findings can help inform policymakers, alongside other considerations, on funding decisions.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"679-687"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budget impact of low-dose computed tomography screening for lung cancer in Argentina. 阿根廷低剂量计算机断层扫描筛查肺癌的预算影响。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-01-30 DOI: 10.1080/14737167.2025.2460523

Constanza Silvestrini, Lucas Perelli, Andrea Alcaraz, Natalia Espinola, Fernando Argento

{"title":"Budget impact of low-dose computed tomography screening for lung cancer in Argentina.","authors":"Constanza Silvestrini, Lucas Perelli, Andrea Alcaraz, Natalia Espinola, Fernando Argento","doi":"10.1080/14737167.2025.2460523","DOIUrl":"10.1080/14737167.2025.2460523","url":null,"abstract":"Background: Lung cancer (LC) is a leading cause of cancer mortality in Argentina. Low-dose computed tomography (LDCT) had demonstrated higher efficacy than chest radiography as a screening method for early detection and reducing LC mortality. This study estimates the Budget Impact of implementing annual LDCT screening for individuals aged 55-74 with at least 30 pack-years of smoking in Argentina.Research design and methods: A budgetary impact model for a dynamic cohort was developed from the Argentine health system's perspective, accounting for LC incidents, prevalents and death probability, distinguishing by disease stage and survival years. Model parameters were sourced from literature and official databases, with costs expressed in 2023 USD.Results: In Argentina, 726,420 individuals were eligible for annual LC screening. The average annual budget was USD 196,611,452 in the current scenario and USD 207,439,560 in the projected scenario, leading to a 5.20% incremental cost due to more false positives in LDCT and screening costs. The budget impact per member per month was USD 0.019, slightly above the estimated threshold of USD 0.015.Conclusions: The introduction of LDCT for LC screening increased the health system budget in Argentina but improved early disease detection.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"689-696"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities. 2022 年意大利生物药品消耗量评估：两家医疗机构的对比分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-20 DOI: 10.1080/14737167.2025.2465445

Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara

{"title":"Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities.","authors":"Marcello Vaccaro, Giacomo Polito, Gabriele Bagaglini, Maurizio Capuozzo, Roberto Langella, Eduardo Nava, Andrea Zovi, Francesco Ferrara","doi":"10.1080/14737167.2025.2465445","DOIUrl":"10.1080/14737167.2025.2465445","url":null,"abstract":"Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend in order to raise awareness among physicians for more appropriate prescribing.Research design and methods: A study was conducted to assess the use of major biologic drugs across different therapeutic areas within two Italian healthcare entities. Usage and cost data were obtained from company databases. In addition, a comparison with 2021 data was performed to identify any increases in biosimilar drug utilization during 2022.Results: The analysis for 2022 revealed that the majority of studied active ingredients have been administered as biosimilar drugs, with percentages close to 100%, except for a few exceptions. In particular, resistance remained in the prescription of biosimilar adalimumab (73.8%) and etanercept (73.3%) in Asl Napoli 3 Sud, erythropoietin (69.5%) and rituximab (72.8%) in Policlinico Umberto I.Conclusions: A comparison between 2021 and 2022 highlighted the increasing adoption of biosimilar drugs. This positive trend suggested the potential for full utilization in the near future, benefiting significantly the National Health System and the public, ensuring a healthcare approach that is effective and sustainable.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"729-735"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How unprofessional behaviours between healthcare staff threaten patient care and safety. 医护人员之间的不专业行为如何威胁病人的护理和安全。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-01-30 DOI: 10.1080/14737167.2025.2460518

Justin Aunger, Jill Maben, Johanna I Westbrook

{"title":"How unprofessional behaviours between healthcare staff threaten patient care and safety.","authors":"Justin Aunger, Jill Maben, Johanna I Westbrook","doi":"10.1080/14737167.2025.2460518","DOIUrl":"10.1080/14737167.2025.2460518","url":null,"abstract":"Introduction: Unprofessional behaviors (UB) such as bullying and incivility among healthcare staff are a significant and pervasive issue, impacting staff wellbeing, and patient safety and experiences of care. Despite its prevalence, misconceptions persist regarding the impact of UB and the mechanisms through which it affects patients.Areas covered: We draw upon evidence including outcomes from an extensive realist review and empirical research, to demonstrate the impacts of UB on patient safety and experience, particularly focusing on how even mild forms of incivility can compromise care quality. Recent research demonstrates a correlation between UB among healthcare professionals and reduced performance, increased medical errors, compromised safety culture, and inequities in patient outcomes. Additionally, we highlight the disproportionate impact of UB on minoritised staff and its resulting effects on patient care, which has the potential to perpetuate healthcare inequities via reducing staff diversity.Expert opinion: Emerging evidence indicates that subtle UB such as incivility and undermining may be more damaging to patient outcomes than previously acknowledged. Addressing UB requires effective, tailored interventions, especially considering the disproportionate impact on diverse healthcare teams. Urgently combating UB is required to not only enhance patient safety but also to improve equity in care in healthcare systems worldwide.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"635-638"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024. 乳腺癌临床试验中结果测量的患者相关性：2014年至2024年间患者偏好和试验的横断面比较分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-20 DOI: 10.1080/14737167.2025.2467379

Jasmijn Plooij, Diana M J Delnoij

{"title":"Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024.","authors":"Jasmijn Plooij, Diana M J Delnoij","doi":"10.1080/14737167.2025.2467379","DOIUrl":"10.1080/14737167.2025.2467379","url":null,"abstract":"Background: Worldwide, many clinical trials are performed using clinical outcomes and surrogate outcomes as endpoints. Surrogate outcomes are used, for instance, if there is not enough follow-up time to measure the outcome of interest. Surrogate outcomes might not be patient-relevant, however. This study assesses to what extent patient-relevant outcomes are measured in clinical trials for breast cancer drugs.Research design and methods: A cross-sectional comparative analysis was conducted in which patient preferences for outcomes derived from the literature were compared to outcomes measured in phase III breast cancer trials conducted between 2014 and 2024.Results: Patients prefer outcomes addressing survival benefits, treatment effectiveness, adverse events and health-related quality of life. Minor improvements in survival benefits are greatly valued. The majority of patients are willing to accept some side effects for a positive outcome. The primary outcome used most frequently in trials is progression-free survival. The most common secondary outcomes are adverse events, mortality, overall response rate, and health-related quality of life.Conclusion: Phase III trial outcomes appear to align largely with breast cancer patients' preferences. Nevertheless, patients and trial designers emphasize different outcomes. Improvement is therefore needed to enhance the relevance of trial data for patients.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"737-742"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China. 公立医院综合改革对慢性阻塞性肺疾病住院患者经济负担的影响——来自西部某试点城市的证据

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-17 DOI: 10.1080/14737167.2025.2480123

Yanghaotian Wu, Jingfu Qiu

{"title":"The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China.","authors":"Yanghaotian Wu, Jingfu Qiu","doi":"10.1080/14737167.2025.2480123","DOIUrl":"10.1080/14737167.2025.2480123","url":null,"abstract":"Background: The Chinese government launched a comprehensive reform of public hospitals, including a zero-markup drug policy (ZMDP) and adjustments to the price compensation mechanism for medical services. We aimed to assess the impact of the reform on economic burden for chronic obstructive pulmonary disease (COPD) inpatients.Research design and methods: Health care institutions were selected using judgmental sampling. Structural variation analysis was conducted to assess changes in the cost structure. An interrupted time series analysis was used to evaluate level and trend changes in medical costs.Results: After the reform, the total cost, western medicine cost, and traditional Chinese medicine cost per visit decreased significantly, with monthly downward trends (p < 0.05). The proportion of western medicine cost decreased by 5.59%, but remained the main composition (31.78%). The health insurance payments, out-of-pocket (OOP) cost per visit, and OOP cost proportion decreased significantly (p < 0.05). The health insurance payments per visit showed a monthly downward trend (p < 0.001), and the decline in OOP cost per visit extended (p = 0.003).Conclusions: The reform reduced the economic burden of COPD inpatients, optimized the cost structure and improved the efficiency of health insurance utilization. However, the short-term substitution effect of medical services on medicines weakened the cost-reduction effect.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"769-779"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis. 帕金森病患者步态冻结结果测量的心理测量特性：系统回顾和荟萃分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-13 DOI: 10.1080/14737167.2025.2477473

Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto

{"title":"Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis.","authors":"Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto","doi":"10.1080/14737167.2025.2477473","DOIUrl":"10.1080/14737167.2025.2477473","url":null,"abstract":"Introduction: This systematic review and meta-analysis evaluated validated tools for assessing FOG in PD, focusing on their psychometric properties, linguistic adaptations, and methodological quality.Methods: A systematic search was conducted in MEDLINE, CINAHL, SCOPUS, and Web of Science, following PRISMA-COSMIN guidelines. Studies assessing validity, reliability, and cross-cultural adaptation of FOG-specific tools were included. Key psychometric properties, such as internal consistency (Cronbach's alpha) and test-retest reliability (Intraclass Correlation Coefficient, ICC), were extracted. The COSMIN Risk of Bias checklist was used to assess methodological quality, and meta-analyses were performed for comparable studies.Results: Six validated tools were identified, with FOG-Q and NFOG-Q emerging as the most robust. Meta-analysis showed high internal consistency (FOG-Q: α = 0.90; NFOG-Q: α = 0.87-0.89) and test-retest reliability (FOG-Q ICC = 0.87), though substantial heterogeneity was noted (I² = 71.1-86.4%). Emerging tools, including CFOG-Q, Ziegler test, and DYPAGS, addressed cognitive and dual-tasking aspects but lacked linguistic validation.Conclusion: FOG-Q and NFOG-Q remain widely used, yet NFOG-Q may have limitations in detecting small clinical changes. Broader linguistic adaptations are needed, and emerging tools hold promise for multidimensional assessment. Future research should integrate subjective and objective measures for comprehensive evaluations.Registration: PROSPERO (CRD42020173873).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"647-659"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indication-based pricing of the pharmaceuticals in Croatia: case-study. 克罗地亚基于适应症的药品定价：案例研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-14 DOI: 10.1080/14737167.2025.2478232

Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković

{"title":"Indication-based pricing of the pharmaceuticals in Croatia: case-study.","authors":"Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković","doi":"10.1080/14737167.2025.2478232","DOIUrl":"10.1080/14737167.2025.2478232","url":null,"abstract":"Background: Rising pharmaceutical expenditure worldwide, including in Croatia, is putting considerable pressure on healthcare budgets. Oncology drugs, often used in several indications with varying efficacy, contribute to this challenge, and a single price is paid regardless of the indication. This study investigates whether indication-based pricing (IBP), a method of pricing the same drug for different indications based on its relative value in different treatment applications, could be a potential solution to contain drug expenditure.Research design and methods: We operationalized IBP in two ways: by anchoring all drug prices according to the indication that provides the most or least benefit, and second, by anchoring drug prices to a cost-effectiveness threshold estimated for Croatia. We also interviewed policymakers in Croatia to determine whether they are familiar with the problem of differential effectiveness of medicines with multiple indications.Results: Applying IBP to the oncology drug abiraterone in three indications, as measured by life-years gained (LYGs) and quality-adjusted life-years (QALYs), shows the effectiveness of abiraterone varies considerably by indication. Depending on the IBP approach chosen, drug prices can be reduced by 74% or increased by up to 280%.Conclusions: Drug prices can vary dramatically depending on the IBP approach chosen.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"761-768"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0